Medina P - Search Results

1

Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.

Cuellar S, McBride A, Medina P. Cuellar S, et al. Among authors: medina p. Am J Health Syst Pharm. 2019 Oct 15;76(21):1725-1738. doi: 10.1093/ajhp/zxz190. Am J Health Syst Pharm. 2019. PMID: 31612935 Review.

2

Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits.

Ignoffo R, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA. Ignoffo R, et al. Among authors: medina p. J Oncol Pract. 2016 Apr;12(4):e359-68. doi: 10.1200/JOP.2015.008490. Epub 2016 Mar 22. J Oncol Pract. 2016. PMID: 27006358

3

Mammalian target of rapamycin: biological function and target for novel anticancer agents.

Borders EB, Bivona C, Medina PJ. Borders EB, et al. Am J Health Syst Pharm. 2010 Dec 15;67(24):2095-106. doi: 10.2146/ajhp100020. Am J Health Syst Pharm. 2010. PMID: 21116000 Review.

4

Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects.

Nightingale G, Schwartz R, Kachur E, Dixon BN, Cote C, Barlow A, Barlow B, Medina P. Nightingale G, et al. Among authors: medina p. J Geriatr Oncol. 2019 Jan;10(1):4-30. doi: 10.1016/j.jgo.2018.06.008. Epub 2018 Jul 13. J Geriatr Oncol. 2019. PMID: 30017734 Review.

5

The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.

Medina P, Jeffers KD, Trinh VA, Harvey RD. Medina P, et al. J Pharm Pract. 2020 Jun;33(3):338-349. doi: 10.1177/0897190019885230. Epub 2019 Nov 6. J Pharm Pract. 2020. PMID: 31694455 Free PMC article.

6

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.

Harvey RD, Adams VR, Beardslee T, Medina P. Harvey RD, et al. Among authors: medina p. J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474. doi: 10.1177/1078155220931926. Epub 2020 Jun 20. J Oncol Pharm Pract. 2020. PMID: 32567494 Free PMC article. Review.

7

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.

Medina PJ, Adams VR. Medina PJ, et al. Pharmacotherapy. 2016 Mar;36(3):317-34. doi: 10.1002/phar.1714. Pharmacotherapy. 2016. PMID: 26822752 Free PMC article. Review.

8

Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation.

Baxley AA, Kumm DE, Bishop CB, Medina PJ, Holter-Chakrabarty J. Baxley AA, et al. J Oncol Pharm Pract. 2013 Sep;19(3):279-83. doi: 10.1177/1078155212464021. Epub 2012 Nov 15. J Oncol Pharm Pract. 2013. PMID: 23154572

9

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.

Zondor SD, Medina PJ. Zondor SD, et al. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1258-64. doi: 10.1345/aph.1D470. Epub 2004 Jun 8. Ann Pharmacother. 2004. PMID: 15187215 Review.

10

Systemic hypersensitivity to fosaprepitant - A report of two cases.

Baxley A, Lee Z, Medina P. Baxley A, et al. Among authors: medina p. J Oncol Pharm Pract. 2018 Jan;24(1):76-78. doi: 10.1177/1078155216680118. Epub 2016 Nov 21. J Oncol Pharm Pract. 2018. PMID: 27872331

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

714 results

Search Page

Filters